Adaptive Biotechnologies Corporation announced increasing use of its clonoSEQ test at the ASH Annual Meeting, with 90 abstracts featuring data. The phase II EndRAD study showcased the benefits of NGS MRD status in guiding clinical decisions for B-ALL patients. Presentations at the meeting highlighted the use of clonoSEQ MRD status in multiple myeloma, non-Hodgkin lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. The data supports the use of clonoSEQ as a precision tool in tailoring treatment intensity or duration for patients with hematologic malignancies. The volume of data at ASH underscores clonoSEQ’s leadership in blood cancer MRD monitoring.

Read more at GlobeNewswire: Adaptive Biotechnologies Showcases Leadership in